ZLAB — Zai Lab Limited | SharesGrow.com

Zai Lab Limited (ZLAB) 是一家生物科技公司，屬於醫療保健產業, 目前交易價格為 $23.25. 其SharesGrow評分為 61/100, 表明高於平均的投資特徵， 7項中通過3項.

分析師共識目標價為 ZLAB = $35 (+50.5% 上漲空間).

估值: ZLAB 本益比(P/E)為 -13.2 (S&P 500平均約25) 前瞻PEG為 0.42.

財務數據: 營收為 $460M, +29.7%/yr 平均成長. 淨利潤為 $176M (虧損), 成長率為 +28.5%/yr. 淨利潤率為 -38.1% (負值). 毛利率為 58.6% (-7 pp 趨勢).

資產負債表: 總債務為 $224M 對比 $716M 股東權益 (D/E比率 0.31, 保守). 流動比率為 2.45 (流動性強). 資產負債率為 19.1%. 總資產: $1.2B.

分析師展望: 9 / 11 位分析師評級 ZLAB 為買入 (82%) — 強烈共識.

SharesGrow 7項標準細分: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 55/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).

$35.00

▲ 50.54% 上漲空間

Average Price Target

The 12-month price target for Zai Lab Limited is $35.00.

ZLAB SharesGrow 評分概覽

71/100

SharesGrow Score

Above average fundamentals

View full scorecard →

價值 100/100

估值 — P/E, PEG, Forward PEG

成長 100/100

財務數據 — 平均成長

過去 0/100

強勁 — 趨勢

健康 67/100

資產負債表 — D/E比率, 流動比率為

護城河 55/100

毛利率為 + market cap

未來 94/100

分析師展望 — 為買入

收入 10/100

淨利潤率為

Scores derived from financial statements, analyst ratings, and balance sheet data.

評分明細 — ZLAB

✓

價值 Pass

100/100

ZLAB 本益比(P/E)為 -13.2 (S&P 500平均約25). Forward PEG 0.42 — Peter Lynch 被低估 (≤1.0). 分析師共識目標價為 $35, 意味著 +50.5% 相對於當前價格 $23. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + 上漲空間 (25%) + trailing PEG (20%). ≥ 60 = Pass.

ZLAB: +29.7%/yr 營收為, +28.5%/yr 淨利潤為平均成長. > 5%/yr — 強勁. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

No analyst coverage available for this stock.

~

健康 Partial

67/100

資產負債表 ZLAB: D/E比率 0.31 (保守), 流動比率為 2.45 (流動性強). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

ZLAB: 毛利率為 58.6% (-7 pp 趨勢), $3B market cap. Moat (0-100): margin (35%) + 趨勢 (15%) + market cap (30%) + 營收為 (20%). Score 55/100. ≥ 70 = Pass.

分析師展望: 9 / 11 位分析師評級 ZLAB 為買入 (82%). 分析師共識目標價為 $35 (+50.5% 上漲空間). Score: 60% buy consensus + 40% 上漲空間. ≥ 60 = Pass.

ZLAB: 淨利潤率為 -38.1%. 負值. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

市場數據

52週區間15.96-44.34

成交量1.18M

30日平均成交量707.54K

市值$2.57B

Beta（1年）0.86

Share Statistics

EPS（TTM）-1.60

流通股數$109.53M

IPO Date2017-09-20

Employees1,869

CEOYing Du

Financial Highlights & Ratios

Revenue (TTM)$460.16M

Gross Profit$269.64M

EBITDA$-158.25M

Net Income$-175.54M

Operating Income$-229.43M

Total Cash$689.57M

Total Debt$224.26M

Net Debt$-455.31M

Total Assets$1.17B

Price / Earnings (P/E)-14.5

Price / Sales (P/S)5.59

Analyst Forecast

1Y Price Target$35.00

Target High$35.00

Target Low$35.00

上漲空間+50.5%

評級共識Buy

覆蓋分析師數11

買入 82% 持有 18% 賣出 0%

Price Target Summary

公司資訊

國家CN

交易所NASDAQ Global Market

貨幣USD

ISINUS98887Q1040

股價走勢

ZLAB

Zai Lab Limited ↗ · NASDAQ Global Market

Healthcare • Biotechnology

15.96 52WK RANGE 44.34

其他人也在看

ALNY

Alnylam Pharmaceuticals, Inc.

Roivant Sciences Ltd.

Madrigal Pharmaceuticals, Inc.

$518.58

-1.22%

RXDX

Prometheus Biosciences, Inc.

$199.92

+0.09%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

KRYS

Krystal Biotech, Inc.

$268.54

-0.54%

Zai Lab Limited ZLAB NASDAQ

ZLAB SharesGrow 評分概覽

評分明細 — ZLAB

Stock Chart & Stats

股價走勢

其他人也在看

獲取低估股票提醒